Literature DB >> 67884

Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine.

P Voytek, J A Beisler, M M Abbasi, M K Wolpert-DeFilippes.   

Abstract

5,6-Dihydro-5-azacytidine hydrochloride, a chemically stable, soluble analog of 5-azacytidine, has cytostatic activity against mouse leukemic L1210 cells grown in culture, but concentrations on the order of 10 micronM, 10-fold higher, than the parent drug, are necessary to inhibit cell growth. The addition of either cytidine or uridine protected against growth inhibition by 5-azacytidine and 5,6-dihydro-5-azacytidine, whereas thymidine potentiated the cytostatic action of both drugs. Deoxycytidine also enhanced the action of 5-azacytidine but had no effect with the reduced analog. Cell suspensions of L1210 cells were able to phosphorylate 5-azacytidine and, to a lesser extent, 5,6-dihydro-5-azacytidine. In cell-free extracts in the presence of ATP and Mg2+, both drugs were converted to nucleotides but at less than 5% the rate of cytidine. As a substrate for mouse kidney cytidine deaminase, the apparent Km value for 5,6-dihydro-5-azacytidine (33 micronM) is of the same order of magnitude as that for cytidine (37 micronM) but less than that for 5-azacytidine (2.1 X 10(3) micronM). The Vm for deamination of the reduced analog is one-tenth that for 5-azacytidine. 3,4,5,6-Tetrahydrouridine, a potent inhibitor of cytidine deaminase, is more effective in blocking deamination of 5-azacytidine than 5,6-dihydro-5-azacytidine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 67884

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).

Authors:  G J Peters; S L Sharma; E Laurensse; H M Pinedo
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

2.  Azapyrimidine analogues: inhibition of viral DNA synthesis and protein synthesis in SV40 infected BSC-1 cells.

Authors:  M Johnson-Thompson; D Albury
Journal:  In Vitro Cell Dev Biol       Date:  1988-11

3.  Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-).

Authors:  V I Avramis; W C Powell; R A Mecum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Authors:  May Kung Sutherland; Changpu Yu; Martha Anderson; Weiping Zeng; Nico van Rooijen; Eric L Sievers; Iqbal S Grewal; Che-Leung Law
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

5.  Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor.

Authors:  D S Zaharko; J M Covey; J A Kelley
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice.

Authors:  W C Powell; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  5-aza-2',2'-Difluoro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer.

Authors:  Richard Daifuku; Zhenbo Hu; Yogen Saunthararajah
Journal:  Pharmaceuticals (Basel)       Date:  2017-07-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.